Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.

@article{Dufour2010ContinuousAO,
  title={Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.},
  author={Jean François Dufour and H. -W. Hoppe and Markus H Heim and Beat Helbling and Olivier Maurhofer and Z Szucs-Farkas and Ralph Kickuth and Markus M. Borner and Daniel Candinas and Bettina Saar},
  journal={The oncologist},
  year={2010},
  volume={15 11},
  pages={1198-204}
}
BACKGROUND AND AIM It is unknown whether sorafenib can be combined with transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. This study assesses the safety and tolerability of a continuous regimen of sorafenib combined with TACE. METHODS This was an open-label phase I study testing a continuous administration of sorafenib (dose escalation from 200 mg twice daily [bid] to 400 mg bid) starting 7 days prior to TACE with doxorubicin (50 mg). RESULTS Twenty-one… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 49 extracted citations

Similar Papers

Loading similar papers…